These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12857550)

  • 1. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
    Konopleva M; Cheng SC; Cortes JE; Hayes KJ; Pierce SA; Andreeff M; Giles FJ; O'Brien S; Kantarjian HM; Estey EH
    Haematologica; 2003 Jul; 88(7):733-6. PubMed ID: 12857550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of prognostic variables in childhood acute myeloid leukemia].
    Gu LJ; Tie LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Ye H; Wang YP; Dong L
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):10-3. PubMed ID: 16732931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
    Haferlach T; Kern W; Schoch C; Schnittger S; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
    Haematologica; 2004 Apr; 89(4):408-18. PubMed ID: 15075074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
    Marcucci G; Mrózek K; Ruppert AS; Archer KJ; Pettenati MJ; Heerema NA; Carroll AJ; Koduru PR; Kolitz JE; Sterling LJ; Edwards CG; Anastasi J; Larson RA; Bloomfield CD
    J Clin Oncol; 2004 Jun; 22(12):2410-8. PubMed ID: 15197203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
    Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
    van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
    Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel.
    Stark B; Jeison M; Gabay LG; Mardoukh J; Luria D; Bar-Am I; Avrahami G; Kapeliushnik Y; Sthoeger D; Herzel G; Steinberg DM; Cohen IJ; Goshen Y; Stein J; Zaizov R; Yaniv I
    Br J Haematol; 2004 Aug; 126(3):320-37. PubMed ID: 15257704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia.
    Marzac C; Teyssandier I; Calendini O; Perrot JY; Faussat AM; Tang R; Casadevall N; Marie JP; Legrand O
    Clin Cancer Res; 2006 Dec; 12(23):7018-24. PubMed ID: 17145823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation.
    Kim DH; Sohn SK; Kim JG; Lee NY; Sung WJ; Baek JH; Suh JS; Lee KS; Lee KB
    Ann Hematol; 2005 Jan; 84(1):25-32. PubMed ID: 15349754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis.
    Hussein K; Ketterling RP; Hulshizer RL; Kuffel DG; Wiktor AE; Hanson CA; Tefferi A; Van Dyke DL
    Eur J Haematol; 2008 Apr; 80(4):318-21. PubMed ID: 18088399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
    Knipp S; Hildebrand B; Kündgen A; Giagounidis A; Kobbe G; Haas R; Aul C; Gattermann N; Germing U
    Cancer; 2007 Jul; 110(2):345-52. PubMed ID: 17559141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
    Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
    Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.